Clinical Trial Proves Effectiveness of Pyratine LLC’s Skin Care Products
(PRWEB) July 23, 2013 -- Pyratine LLC, a leading researcher and developer of novel proprietary skin care products, is pleased to announce the results of an important clinical trial that affirms the effectiveness of PyratineXR®, a superior anti-inflammatory compound developed for the treatment of rosacea. This clinical trial, performed under the leadership of the prestigious Department of Dermatology, University of California at Irvine, is particularly notable given that non-prescription skin care products are not required to undergo scientific testing, especially human clinical trials using US Food and Drug Administration stringent protocols, which this trial used.
Conducted over a period of 48 weeks, the clinical trial demonstrated the value of PyratineXR® as an agent for the treatment of rosacea, a common skin disorder afflicting all skin types, most notably fair-skinned persons, and affecting over 16 million Americans alone. Rosacea patients who participated in the trial reported rapid results, noting healthier looking skin within the first week of treatment, progressing to a dramatic 44.5% decrease in erythema (redness) and an 82% reduction in inflammatory lesions by week 36; further, investigators reported a 27.8% decrease in telangiectasia after 36 weeks.
In addition to reducing the key symptoms associated with rosacea, PyratineXR® is suitable for long-term use, unlike many competing products on the market that become ineffective over continuous use or cannot be used safely for an extended period of time. This makes PyratineXR® an ideal choice for the millions of people worldwide who suffer from rosacea.
PyratineXR® is a significant advancement in plant growth factors known as cytokinins and differentiates itself by having anti-inflammatory properties to reduce redness, papules and pustules while ameliorating the signs of aging by reducing fine lines, wrinkles, mottled hyperpigmentation and skin roughness. Pyratine LLC’s first development was kinetin, marketed by Valeant Pharmaceuticals as Kinerase®; PyratineXR® is a significant advancement over kinetin, a “Super Kinetin”, working much faster and being much more efficacious than kinetin.
To order, customers may contact Pyratine LLC at 888-467-9728 (877-737-7546 outside the U.S. and Canada) or visit the company’s website at http://www.pyratine.com.
About Pyratine LLC
Pyratine LLC is a Specialty Therapeutic Development Company engaged in the discovery and research of technologies that target unmet needs in skin care and dermatology. The Company’s extensive research collaborations worldwide have resulted in a strong pipeline of proprietary compounds with broad therapeutic applications and a leading presence in dermatology. The Company is the developer of the top selling anti-aging product in the North American Physician Market as well as a best-selling skin care line in the Prestige Channel of Distribution. The Company’s scientific staff consists of thought leaders in skin care, one of whom was a Nobel Prize winner in Chemistry in 1997. Out of Pyratine LLC’s concern for safety, the Company standards for product development and production exceed the FDA requirements for non-prescription products.
Contact Us, Pyratine LLC, http://www.pyratine.com/, 1.877.737.7546, [email protected]
Share this article